KR20100014397A - 아데노신 에이투에이 수용체 길항제 - Google Patents

아데노신 에이투에이 수용체 길항제 Download PDF

Info

Publication number
KR20100014397A
KR20100014397A KR1020097019161A KR20097019161A KR20100014397A KR 20100014397 A KR20100014397 A KR 20100014397A KR 1020097019161 A KR1020097019161 A KR 1020097019161A KR 20097019161 A KR20097019161 A KR 20097019161A KR 20100014397 A KR20100014397 A KR 20100014397A
Authority
KR
South Korea
Prior art keywords
pyrrolo
triazolo
pyrimidin
furan
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020097019161A
Other languages
English (en)
Korean (ko)
Inventor
알. 무어만 알란
Original Assignee
킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 filed Critical 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨
Publication of KR20100014397A publication Critical patent/KR20100014397A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020097019161A 2007-03-30 2008-03-28 아데노신 에이투에이 수용체 길항제 Withdrawn KR20100014397A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US90910607P 2007-03-30 2007-03-30
US60/909,106 2007-03-30
US12/056,423 US7723343B2 (en) 2007-03-30 2008-03-27 Adenosine A2A receptor antagonists
US12/056,403 2008-03-27
US12/056,403 US7691869B2 (en) 2007-03-30 2008-03-27 Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
US12/056,423 2008-03-27

Publications (1)

Publication Number Publication Date
KR20100014397A true KR20100014397A (ko) 2010-02-10

Family

ID=39795488

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097019161A Withdrawn KR20100014397A (ko) 2007-03-30 2008-03-28 아데노신 에이투에이 수용체 길항제

Country Status (12)

Country Link
US (2) US7691869B2 (enExample)
EP (1) EP2129220A4 (enExample)
JP (1) JP2010523497A (enExample)
KR (1) KR20100014397A (enExample)
CN (1) CN101652067A (enExample)
AU (1) AU2008232690A1 (enExample)
BR (1) BRPI0808438A2 (enExample)
CA (1) CA2680075A1 (enExample)
IL (1) IL201234A0 (enExample)
MX (1) MX2009010223A (enExample)
NZ (1) NZ578720A (enExample)
WO (1) WO2008121748A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2657973A1 (en) * 2006-06-27 2008-01-03 Biovitrum Ab (Publ) Therapeutic compounds
RS54560B1 (sr) 2008-06-10 2016-06-30 Abbvie Inc. Triciklična jedinjenja
SG171890A1 (en) * 2008-12-03 2011-07-28 Presidio Pharmaceuticals Inc Inhibitors of hcv ns5a
CA2755117C (en) 2009-03-13 2018-09-11 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
RU2012127368A (ru) 2009-12-01 2014-01-10 Эбботт Лэборетриз Новые трициклические соединения
CN102711476B (zh) 2009-12-01 2014-12-03 Abbvie公司 新的三环化合物
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
CA2812378C (en) * 2010-09-24 2016-11-29 Advinus Therapeutics Limited Fused tricyclic compounds as adenosine receptor antagonist
US20120330012A1 (en) * 2011-04-29 2012-12-27 Abbott Laboratories Novel Tricyclic Compounds
WO2015027431A1 (en) * 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. 2,2-difluorodioxolo a2a receptor antagonists
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
RU2018117889A (ru) 2015-10-16 2019-11-20 Эббви Инк. СПОСОБЫ ПОЛУЧЕНИЯ (3S,4R)-3-ЭТИЛ-4-(3H-ИМИДАЗО[1,2-a]ПИРРОЛО[2,3-e]-ПИРАЗИН-8-ИЛ)-N-(2,2,2-ТРИФТОРЭТИЛ)ПИРРОЛИДИН-1-КАРБОКСАМИДА И ЕГО ТВЕРДОФАЗНЫХ ФОРМ
WO2018035391A1 (en) * 2016-08-19 2018-02-22 Bristol-Myers Squibb Company Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of making and use
LT3601296T (lt) * 2017-03-30 2022-09-26 iTeos Belgium SA 2-okso-tiazolo derivatai kaip a2a inhibitoriai ir junginiai, skirti naudoti gydant vėžį
AU2019385905B2 (en) 2018-11-30 2023-01-12 Merck Sharp & Dohme Llc 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
DE69428977T2 (de) 1993-07-27 2002-07-11 Kyowa Hakko Kogyo Co., Ltd. Arzneimittel gegen Parkinsonsche Krankheit
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
TWI288137B (en) 2000-05-26 2007-10-11 Schering Corp Adenosine A2a receptor antagonists
PE20030477A1 (es) 2001-10-15 2003-06-06 Schering Corp ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a
US6916811B2 (en) 2001-11-30 2005-07-12 Schering Corporation Adenosine A2a receptor antagonists
AU2003245380A1 (en) 2002-05-30 2003-12-19 King Pharmaceuticals Research & Development, Inc. Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
US20060128694A1 (en) 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
ES2326270T3 (es) 2003-04-23 2009-10-06 Schering Corporation Antagonistas del receptor de la adenosina a2a 2-alquinil- y 2-alquenil-pirazolo-(4,3-e)-1,2,4-triazolo-(1,5-c)-pirimidina.
NZ550591A (en) 2004-04-21 2010-10-29 Schering Corp Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2A receptor antagonists
US7465740B2 (en) 2005-09-19 2008-12-16 Schering Corporation 2-heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
PE20070521A1 (es) 2005-09-23 2007-07-13 Schering Corp 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a

Also Published As

Publication number Publication date
AU2008232690A1 (en) 2008-10-09
EP2129220A2 (en) 2009-12-09
US7691869B2 (en) 2010-04-06
JP2010523497A (ja) 2010-07-15
US20080242672A1 (en) 2008-10-02
IL201234A0 (en) 2010-05-31
AU2008232690A2 (en) 2009-12-10
CA2680075A1 (en) 2008-10-09
MX2009010223A (es) 2009-10-26
BRPI0808438A2 (pt) 2014-07-29
WO2008121748A2 (en) 2008-10-09
NZ578720A (en) 2011-01-28
CN101652067A (zh) 2010-02-17
US7723343B2 (en) 2010-05-25
US20080242673A1 (en) 2008-10-02
WO2008121748A3 (en) 2009-09-11
EP2129220A4 (en) 2010-12-29

Similar Documents

Publication Publication Date Title
KR20100014397A (ko) 아데노신 에이투에이 수용체 길항제
RU2632870C2 (ru) Трициклические гетероциклические соединения и ингибиторы jak
JP4284181B2 (ja) アデノシンＡ２ａレセプターアンタゴニスト
US6586421B2 (en) Substituted azepino[4,5b]indoline derivatives
ES2342082T3 (es) Antagonistas de receptores a2a de adenosina de pirazolo(4,3-e)-1,2,4-triazolo(1,5-c)pirimidina.
ES2283625T3 (es) Antagonistas del receptopr a2a de adenosina de (1,2,4)-triazol biciclicos.
ES2327145T3 (es) Anatagonistas del receptor de adenosina a2a de pirazolo(1,5-a)pirimidina sustituidos.
JP2010526138A (ja) ピロロピリミジン−７−オン誘導体とその薬剤としての使用
US20110015185A1 (en) Benzofuran Compounds
TW202110845A (zh) 三環化合物
CA2669447A1 (en) Allosteric modulators of the a1 adenosine receptor
JP4194539B2 (ja) アゾロトリアジン類およびアゾロピリミジン類
US20110053917A1 (en) Allosteric Modulators of the A1 Adenosine Receptor
US8785453B2 (en) Arylpiperazine-containing purine derivatives and uses thereof
US20080119460A1 (en) Allosteric modulators of the a1 adenosine receptor
HK1064100B (en) Adenosine a 2a receptor antagonists

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090914

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid